Home / Prices / Platelet-Rich Fibrin (PRF) therapy

Platelet-Rich Fibrin (PRF) therapy

Dermatology & Aesthetics estimated about CNY 3000-6500

Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer

Description

A regenerative medical procedure using autologous platelet-rich fibrin membranes or injectable PRF to enhance tissue healing, bone regeneration, and soft-tissue repair in dentistry, orthopedics, and dermatology.

Main Uses

PRF autologous regenerative therapy is primarily used in oral and maxillofacial surgery (e.g., socket preservation, sinus lift, ridge augmentation, periodontal defect regeneration), orthopedics (tendon/ligament healing, osteoarthritis intra-articular injection), dermatology (chronic wound healing, alopecia, facial rejuvenation), and ENT (tympanic membrane repair). Its main purposes include accelerating soft and hard tissue healing, modulating inflammation, delivering sustained-release growth factors, enhancing angiogenesis, and serving as a natural scaffold for cell migration—without exogenous additives or animal-derived components.

Normal Range

PRF (Platelet-Rich Fibrin) is not a standardized blood test with quantitative 'normal ranges' like conventional lab assays. It is an autologous biologic preparation derived from centrifuged venous blood; therefore, no universal numerical reference intervals exist for 'PRF levels'. Instead, quality assessment focuses on qualitative and semi-quantitative parameters: platelet concentration (typically 3–8× baseline whole blood), fibrin matrix density (visual/tactile evaluation), leukocyte content (moderate to high, depending on centrifugation protocol), and growth factor release kinetics (e.g., PDGF-BB, TGF-β1, VEGF — measured in research settings only, not clinically routine). Clinical protocols define success by morphological integrity (intact, cohesive clot), color (amber-yellow), elasticity, and absence of hemolysis or serum separation.

Low Values - Possible Causes

1. Inadequate venous blood draw volume or improper collection tube (non-additive or EDTA tubes inhibit fibrin polymerization); 2. Suboptimal centrifugation parameters (insufficient g-force, duration, or incorrect brake setting causing clot disruption); 3. Patient-related factors including severe thrombocytopenia (<100 × 10⁹/L), chronic platelet dysfunction (e.g., aspirin/NSAID use within 7–10 days), advanced age (>75 years), uncontrolled diabetes, or systemic inflammation; 4. Anticoagulant therapy (e.g., warfarin, DOACs) interfering with fibrin formation; 5. Hemodilution or acute blood loss prior to collection.

High Values - Possible Causes

1. Excessive centrifugal force or prolonged spin time leading to over-compaction, reduced bioactivity, and diminished growth factor retention; 2. High baseline platelet count (thrombocytosis >450 × 10⁹/L), often associated with reactive or clonal myeloproliferative disorders; 3. Acute inflammatory states (e.g., active infection, recent surgery) increasing circulating leukocytes and cytokines incorporated into PRF; 4. Use of low-speed, single-spin protocols that retain excessive red blood cells (RBCs), falsely elevating total clot mass but compromising purity and clinical efficacy; 5. Operator-dependent variability in tube filling and handling causing inconsistent fibrin network architecture.

TMD therapy autologous regenerative medicine platelet-rich fibrin dental bone grafting growth factor therapy

estimated about CNY 3000-6500